Human metapneumovirus (HMPV) is a recently identified paramyxovirus that is a major cause of upper and lower respiratory tract infections in infants and children worldwide \[[@r1]\] and among immunocompromised persons or those with other underlying chronic medical conditions \[[@r8]\]. HMPV infection appears to be ubiquitous, as virtually all children are seropositive by the age of 5 years \[[@r3], [@r16]\]. Previous estimates of the percentage of acute pediatric lower respiratory tract infections associated with HMPV range from 5% to 25% \[[@r2], [@r4], [@r5], [@r7], [@r19]\], with differences likely resulting from various geographic areas being studied, seasonal variability in HMPV circulation, methodological differences, and age groups evaluated. Reinfection occurs throughout life, but subsequent infections are more likely to present with upper respiratory symptoms than with lower respiratory symptoms and to be milder in character than primary infection \[[@r1], [@r2]\].

Despite studies demonstrating the prevalence of HMPV infection, its actual population-wide disease burden is poorly understood. This study had 3 objectives. First, we sought to establish population-based rates of HMPV-associated infection in hospitalized children \<5 years old with acute respiratory symptoms or fever. Second, we sought to compare the burden of HMPV infection with that of other respiratory virus infections. Finally, although earlier studies outlined the clinical characteristics of HMPV infection on convenience samples, we wished to comprehensively characterize the clinical presentations from a population-wide perspective.

Methods
=======

***Study design.*** The New Vaccine Surveillance Network was established by the Centers for Disease Control and Prevention to determine the burden of acute respiratory illness (ARI) from vaccine-preventable or potentially preventable agents and to monitor the impact of vaccine use on disease rates \[[@r22]\]. Prospective population-based surveillance was conducted among children \<5 years of age who were hospitalized with acute respiratory symptoms or fever anytime from 1 October 2001 through 30 September 2003 in area hospitals that provided care for \>95% of hospitalized children in Davidson County, Tennessee (Nashville), and Monroe County, New York (Rochester). The institutional review boards at both study sites, the participating hospitals, and the Centers for Disease Control and Prevention approved the study.

The current study used previously published methods to establish the burden of HMPV infection in hospitalized children \[[@r23]\]. Eligible hospitalized children were \<5 years of age and had received an admission diagnosis of fever alone or of acute respiratory infection, which was defined as an illness presenting with fever and/or 1 or more of the following symptoms: cough, earache, nasal congestion, rhinorrhea, sore throat, vomiting after coughing, wheezing, and labored, rapid, or shallow breathing. Children were excluded if they had respiratory symptoms that had lasted \>14 days at the time of admission, had neutropenia from chemotherapy, were hospitalized elsewhere within the preceding 4 days, or were newborns who had been hospitalized since birth. Study nurses enrolled children admitted to surveillance hospitals from Sunday through Thursday, after obtaining written informed consent. Children were eligible for enrollment if they were admitted within 48 h of an enrollment day. Nasal and throat specimens were obtained with swabs from all children on the day of enrollment (thus within 48 h of admission), combined into a single tube of viral transport medium, and promptly delivered to the research laboratories at the study sites. Demographic and clinical information was collected using a standardized questionnaire, as described elsewhere \[[@r22], [@r26]\]. We performed statistical comparisons between children infected with HMPV alone and children infected with other specific viruses alone; children with \>1 virus detected in their specimens were excluded from analysis. Children were considered to be virus-negative if their specimens tested negative for HMPV, influenza virus, respiratory syncytial virus (RSV), parainfluenza virus (PIV), human rhinovirus (HRV), and human coronavirus by testing methods that are described below. Highrisk conditions were assessed, which included history of asthma, heart disease, sickle cell anemia, cystic fibrosis, diabetes mellitus, and neuromuscular conditions such as seizures, cerebral palsy, or muscular dystrophy. History of asthma was determined by asking the parents if their child had ever received a diagnosis of asthma from any health care provider or by documentation of a previous diagnosis of asthma in the medical record \[[@r24]\].

***Molecular testing.*** Specimens were divided into aliquots and stored at -80°C until processing. RNA was extracted from pooled nasal and throat swab medium. Specimens were tested for HMPV by real-time reverse-transcription polymerase chain reaction (RT-PCR), as described elsewhere \[[@r1], [@r27]\]. Specimens were also tested for influenza virus, RSV, PIV, HRV, and human coronavirus by real-time RT-PCR \[[@r23], [@r28], [@r29]\]. Specimens that tested positive for HMPV were subjected to conventional nested RT-PCR to amplify and sequence complementary DNA of the F and G genes, as described elsewhere \[[@r1]\]. HMPV subgroup assignment was made on the basis of either the F or the G gene; either gene reliably identifies the viral subgroup \[[@r30]\]. Sequences were edited and aligned with published HMPV sequences obtained from GenBank by means of the ClustalW algorithm in MacVector software (version 10.0; Accelrys). Phylogenetic analyses were performed using Mega software (version 4) \[[@r31]\]. The data sets were resampled with 500 bootstraps, distances were computed using the maximum composite likelihood method, and phylogeny was inferred using the neighbor-joining method \[[@r31]\]. Analyses that made use of the maximum parsimony and minimum evolution methods yielded similar results (data not shown), and so only the results of the neighbor-joining analysis are shown.

***Data analysis.*** The number of hospitalized children with laboratory-confirmed HMPV infection per 1000 children was calculated as the weighted number of HMPV-positive hospitalized children with ARI or fever divided by the number of children in the county population as determined by the 2000 US Census, multiplied by 1000 \[[@r22], [@r29]\]. Rates were calculated by weighting the observed number of enrolled hospitalized children to account for sampling 5 days per week and eligible patients who were not enrolled. Rates were determined overall and by demographic subsets with 95% confidence intervals (CIs) calculated using 1000 bootstrap samples.

Kruskal-Wallis or Pearson tests were used as appropriate for contingency table analyses of signs and symptoms associated with HMPV infection alone compared with infection with RSV, influenza virus, PIV, or HRV alone, or compared with virusnegative children. Influenza virus included influenza A and B viruses; PIV included PIV types 1, 2, and 3. For comparative analyses, children with coinfections were excluded. Prospectively collected demographic and clinical data were compared among children with different viral infections and virus-negative children. Age was categorized as 1 of 3 groups (\<6, 6--23, and \>23 months), on the basis of prior studies of respiratory viruses among this population \[[@r22], [@r23], [@r25], [@r26], [@r29]\]. All analyses were performed using R software (version 2.6.2; see http:// www.R-project.org).

Results
=======

***Study population.*** Of 1298 children admitted to the surveillance hospitals with respiratory symptoms or fever during enrollment days over the 2-year period, 1123 (86.5%) were enrolled. Of 175 children who were not enrolled, 87 (49.7%) had parents and/or guardians who refused participation, 62 (35.4%) had no parents and/or guardians available, 16 (9.1%) were discharged before enrollment, and 10 (5.7%) were not enrolled because of missed admission, unavailability of an interpreter, or refusal of the physician to allow participation. Sufficient specimens for HMPV testing were available for 1104 (98.3%) of 1123 study children. Thus, a total of 1104 children were included in the study.

***Demographic characteristics of children infected with HMPV alone compared with those of children infected with other sin*** ***gle viruses.*** Of the 1104 specimens tested, 42 (3.8% \[95% CI, 2.8%--5.1%\]) were positive for HMPV, with similar rates in both study years (4.2% in 2001--2002 and 3.3% in 2002--2003) and at both study sites. Demographic characteristics of children with HMPV, RSV, influenza virus, PIV, or HRV infection alone or with no virus detected are presented in [Table 1](#t1){ref-type="fig"}. The median age of children who tested positive for HMPV alone was 6 months (range, 2--13 months), similar to the median age of those with RSV infection or influenza, whereas children with PIV or HRV infection were older. Sex, race, history of premature birth, and insurance status did not differ between groups. Attendance in out-of-home daycare was less common among children with HMPV infection and those with influenza, compared with those with RSV, PIV, or HRV infection. Children with HMPV infection and children with influenza had slightly higher rates of exposure to household tobacco smoke, compared with children in other groups. Proportions of general high-risk status (including asthma) were higher among children with HMPV or HRV infection, whereas proportions of underlying asthma alone were similar between children with HMPV infection, RSV infection, or no virus identified. Underlying asthma alone was more common among children with HRV infection and less common among children with influenza.
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***Rates of HMPV-associated hospitalization and seasonal trends.*** Population-based rates of HMPV infection in hospitalized children are presented in [Table 2](#t2){ref-type="fig"}, along with previously published rates of infection with other common viruses in the New Vaccine Surveillance Network cohort during time periods that overlapped this study period \[[@r23], [@r25], [@r29]\]. The overall annual incidence was 1.2 HMPV-associated hospitalizations (95% CI, 0.9--1.6) per 1000 children \<5 years of age; the age-specific incidence was highest among younger children: 4.9 (95% CI, 2.9- 7.2) for children 0--5 months of age, 2.9 (95% CI, 1.4--4.7) for children 6--11 months of age, 0.7 (95% CI, 0.1--1.4) for children 12--23 months of age, and 0.4 (95% CI, 0.1--0.7) for children 24--59 months of age. The incidence of HMPV was highest in the 0--5-month-old and 6--11-month-old age groups, although RSV infection remained more common than HMPV infection in these age groups. The incidence of HMPV infection in other age groups was similar to that of influenza and PIV-3 infection.
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The number of all specimens collected (including HMPVpositive specimens and HMPV-negative specimens) peaked during January, with 55% of all specimens collected between 1 October and 28 February during both study years ([Figure 1](#f1){ref-type="fig"}). However, detection of HMPV in specimens peaked slightly later in both years, with 80% of all HMPV infections occurring between 1 February and 31 May during both study years. The percentage of patients who tested HMPV-positive by month varied from 0 during the summer months to a peak of 15% during April.
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***Clinical characterization of HMPV infections.*** Clinical features of children infected with HMPV or other viruses are shown in [Table 3](#t3){ref-type="fig"}. The majority of HMPV-infected children had fever, rhinorrhea, cough, poor feeding, and/or difficulty breathing. Although most of these symptoms were also present in children infected with other respiratory viruses, fever was less common among children with HMPV infection than among children with influenza. Conversely, difficulty breathing and wheezing were more common among HMPV-infected children than among children with influenza or children with no virus detected. Sore throat was most common among children with HMPV or PIV infection. Thirty-eight percent of the HMPVinfected children required supplemental oxygen, and 2% were treated in the intensive care unit; these proportions were similar to those for other viruses. No child with HMPV infection in this study died, and the mean duration of hospitalization was 2 days, similar for all viruses. Thirteen children with HMPV detection had codetection of other viruses, including 6 with HRV detection, 4 with influenza virus detection, 2 with RSV detection, and 1 with PIV-3 detection. The most common discharge diagnoses among children with HMPV infection only were bronchiolitis (38%), pneumonia (24%), asthma (24%), and upper respiratory tract infection (3%). Bronchiolitis was most common among children with HMPV or RSV infection, whereas pneumonia was more common among HMPV-infected children. A discharge diagnosis of asthma was common in all groups but was less frequent among children with influenza (9%) and most frequent among HRV-infected children (46%). Other diagnoses included croup in a substantial number of children with influenza and PIV infection \[[@r25], [@r29]\] and febrile illness alone in children with no respiratory virus identified.
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***HMPV diversity.*** HMPV-positive specimens were tested by means of RT-PCR for the F and G genes, and 27 (61%) were genotyped; not all specimens were successfully amplified for F or G by means of RT-PCR because of RNA degradation. All 4 subgroups of HMPV were detected in both years; overall, subgroup A1 was the most prevalent (44.4%), followed by A2 (29.6%), B1 (18.5%), and B2 (7.4%). However, the distribution of subgroups varied between years, with A1 dominant in the first year and A2 and B1 detected with equal frequency in the second year ([Figure 2](#f2){ref-type="fig"}). There were no differences between the prevalence of the subgroups by study site. No differences in disease severity were noted between the subgroups (data not shown). Phylogenetic analysis showed genetic diversity even within each of these subgroups, with analysis of the F gene sequences showing 2 sublineages of the A2 subgroup ([Figure 3*A*](#f3){ref-type="fig"}) and analysis of the G gene sequences showing 2 sublineages of the B1 subgroup ([Figure 3*A*](#f3){ref-type="fig"}). Both of these sublineages circulated during the same season and at the same study site and thus were not unique to either site or year.
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![Phylogenetic tree depicting the relationships among human metapneumovirus (HMPV) F sequences (*A*) and G sequences (*B*) identified in this study. Phylogeny was inferred using the neighbor-joining method with 500 bootstrap replicates, as described in Methods. Branches reproduced in \<50% of the bootstrap replicates are collapsed. The percentage of replicate trees in which the associated taxa clustered together in the bootstrap test is shown next to the branches. The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic tree. *Diamonds* , prototypical GenBank strains. The scale bar indicates nucleotide substitutions per site. Sequences identified in this study have been submitted to GenBank.](201-12-1890-fig003){#f3}

Discussion
==========

We used prospective, population-based, laboratory-confirmed active surveillance to define the burden of HMPV infection among hospitalized young children. The contribution of HMPV infection to pediatric hospitalization for ARI or fever was substantial, with 1.2 hospitalizations per 1000 children \<5 years old per year (95% CI, 0.9--1.6), compared with 3.0 per 1000 (95% CI, 2.8--3.4) for RSV, 0.9 per 1000 (95% CI, 0.8--1.1) for influenza virus, and 0.5 per 1000 (95% CI, 0.4--0.6) for PIV-3 \[[@r23], [@r25], [@r29]\]. The rate of HMPV-associated hospitalization was highest among infants 0--5 months old, at 4.9 per 1000 (95% CI, 2.9--7.2), compared with 16.9 per 1000 (95% CI, 15.3--18.5) for RSV, 4.5 per 1000 (95% CI, 3.4--5.5) for influenza virus, and 1.6 per 1000 (95% CI, 1.0--2.2) for PIV-3 \[[@r23], [@r25], [@r29]\]. These data suggest that HMPV causes hospitalizations for respiratory symptoms and fever in children \<5 years old at rates similar to those of influenza virus and PIV. If we extrapolate from US Census data, then our data would project ∼27,000 HMPV-related hospitalizations of children \<5 years of age annually, which underscores the impact of HMPV infection on children. HMPV is rarely detected in asymptomatic young children \[[@r2], [@r3], [@r32], [@r33]\].

Although there have been reports of HMPV disease in children with underlying medical conditions, such as premature birth or asthma, few of these studies have been populationbased and have enrolled as many children as were enrolled in the present study \[[@r8], [@r11], [@r19], [@r34], [@r35]\]. One-third of the hospitalized children with HMPV infection in our study had highrisk conditions, which suggests that these children are at higher risk for hospitalization with HMPV infection. However, twothirds of HMPV-infected hospitalized children were otherwise healthy children. We did not observe an association between HMPV hospitalization and a history of asthma, in contrast to the association between asthma and HRV infection that was previously found in this cohort \[[@r24], [@r36]\]. Consistent with previous reports, HMPV infection was associated most frequently with a diagnosis of bronchiolitis \[[@r2], [@r5], [@r7], [@r19], [@r21]\]. The presenting symptoms of HMPV infection in this cohort generally were not distinct from those of children infected with other viruses, consistent with other reports \[[@r1], [@r2], [@r5], [@r7], [@r19], [@r21], [@r37], [@r38]\]. However, very few HMPV-infected children (5%) had fever alone without respiratory symptoms.

HMPV infection was most prominent at both study sites during the late winter and spring months, with peak illness rates in March, April, and May. Overall, HMPV infection accounted for up to 15% of all hospitalizations for children \<5 years old with ARI or fever with a late spring distribution and was more common than influenza or RSV infection during this time period \[[@r23], [@r25]\]. However, the lack of distinctive clinical symptoms and the overlap with other community respiratory virus infections highlights the potential utility of rapid, sensitive diagnostic tests such as RT-PCR to detect HMPV and other respiratory viruses.

We identified all 4 subgroups of HMPV during each year and at each study site, although the distribution of subgroups varied by year. The extent of antigenic variability between HMPV subgroups is not clear in animals or in humans \[[@r30], [@r39]\], but the presence of multiple HMPV strains in a single season could affect the design of vaccines or prophylactic antibodies if antigenic variability leads to partial immune escape. We did not find that specific subgroups were associated with more severe disease (data not shown); some studies have suggested this phenomenon \[[@r42]\], whereas others have not \[[@r43]\]. Correlation between infecting subtype and disease severity has been shown for RSV infection \[[@r44], [@r45]\]. A postulated mechanism for alternating circulation of different HMPV subgroups is population immune pressure \[[@r46], [@r47]\]. Long-term, prospective, population-based surveillance is needed to establish whether different subgroups of HMPV vary in virulence and whether circulation patterns are the result of immune pressure.

***Study limitations.*** Despite the strength of our prospective population-based surveillance system, our study had limitations. First, surveillance was performed for only 2 years at only 2 geographically distant sites (representing 2 US regions, Northeast and South). Greater regional and temporal differences in viral circulation may have been evident if the study included more years or sites, because other studies have reported substantial year-to-year variability in HMPV infection prevalence \[[@r1]\]. Second, institutional differences in medical practice might have contributed to variation in HMPV-related hospitalization rates, and although enrolled and nonenrolled children did not differ in demographic characteristics, unknown biases may have affected our HMPV infection burden estimates. Coinfections were present in a minority of children, but the clinical importance of these coinfections is not clear. HRV is identified frequently in asymptomatic individuals and thus is especially difficult to interpret as a codetected virus \[[@r48]\]. A large number of children in the study did not have a virus identified by means of the testing used; this could be attributable to false negative test results or to the presence of other pathogens for which we did not test. Nearly all of the HMPV-infected children had ARI symptoms and not fever alone, but we enrolled children with fever alone in addition to children with ARI. Thus, because the population-based incidence was calculated with all hospitalized children, including those with fever alone, we may have underestimated the true incidence of infection with HMPV (and other viruses) among children with ARI. Finally, this study only assessed hospitalized children, and the impact of HMPV infection on emergency department and outpatient visits is unknown.

***Conclusion.*** HMPV infection is a leading cause of hospitalization for ARI among children \<5 years of age, with a population-based incidence similar to that of influenza and PIV-3 infection. The majority of HMPV-associated hospitalizations occurred among otherwise healthy children. These data suggest a need for preventive and therapeutic strategies for HMPV infection and highlight the need to consider HMPV infection as a cause of ARI among hospitalized children, especially in the spring.
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